Display options
Share it on

Interdiscip Perspect Infect Dis. 2013;2013:941392. doi: 10.1155/2013/941392. Epub 2013 Jul 17.

Atherosclerosis Induced by Chlamydophila pneumoniae: A Controversial Theory.

Interdisciplinary perspectives on infectious diseases

Hamidreza Honarmand

Affiliations

  1. Department of Microbiology, Guilan University of Medical Sciences, Iran ; Heart Research Center, Guilan University of Medical Sciences, Iran.

PMID: 23956742 PMCID: PMC3730386 DOI: 10.1155/2013/941392

Abstract

More than a century ago, inflammation and infection were considered to have atherogenic effects. The old idea that coronary heart disease (CHD) possibly has an infectious etiology has only reemerged in recent years. Atherosclerosis is the main pathological process involved in CHD and is, logically, the first place to look for infectious etiology. The process of atherosclerosis itself provides the first hints of potential infectious cause. Smooth muscle proliferation, with subsequent intimal thickening, luminal narrowing, and endothelial degeneration, constitutes the natural history of atherosclerosis, being with the severity and speed of these changes. Both viral and bacterial pathogens have been proposed to be associated with the inflammatory changes found in atherosclerosis. Recently, Chlamydophila pneumoniae (C. pneumoniae) has been implicated as a possible etiologic agent of coronary artery disease and atherosclerosis. New evidence which supports a role for C. pneumoniae in the pathogenesis of atherosclerosis has emerged. C. pneumoniae has been detected in atherosclerotic arteries by several techniques, and the organism has been isolated from both coronary and carotid atheromas. Recent animal models have suggested that C. pneumoniae is capable of inducing atherosclerosis in both rabbit and mouse models of atherosclerosis. Furthermore, human clinical treatment studies which examined the use of antichlamydial macrolide antibiotics in patients with coronary atherosclerosis have been carried out. The causal relationship has not yet been proven, but ongoing large intervention trials and research on pathogenetic mechanisms may lead to the use of antimicrobial agents in the treatment of CHD in the future.

References

  1. Circulation. 1999 Mar 9;99(9):1161-4 - PubMed
  2. Proc Natl Acad Sci U S A. 1993 May 1;90(9):3998-4002 - PubMed
  3. Am J Pathol. 1997 May;150(5):1785-90 - PubMed
  4. Circulation. 2002 Feb 19;105(7):861-7 - PubMed
  5. Circulation. 1997 Jul 15;96(2):404-7 - PubMed
  6. Atherosclerosis. 1997 Jan 3;128(1):27-38 - PubMed
  7. Stroke. 1999 Feb;30(2):299-305 - PubMed
  8. Lancet. 1996 Mar 23;347(9004):781-6 - PubMed
  9. Heart Vessels. 1997;Suppl 12:76-80 - PubMed
  10. Prog Cardiovasc Nurs. 2003 Winter;18(1):42-9 - PubMed
  11. Microbiol Rev. 1994 Dec;58(4):686-99 - PubMed
  12. J Clin Invest. 1984 Nov;74(5):1890-4 - PubMed
  13. J Lipid Res. 1989 Jan;30(1):39-49 - PubMed
  14. Arterioscler Thromb. 1994 Jan;14(1):47-53 - PubMed
  15. J Clin Invest. 1995 Dec;96(6):2569-77 - PubMed
  16. J Lipid Res. 1993 Dec;34(12):2147-58 - PubMed
  17. Atherosclerosis. 2007 Oct;194(2):403-7 - PubMed
  18. Microb Pathog. 1996 Sep;21(3):215-21 - PubMed
  19. Biol Res Nurs. 2004 Jul;6(1):3-10 - PubMed
  20. Infect Immun. 1998 Nov;66(11):5067-72 - PubMed
  21. J Am Coll Cardiol. 1999 Nov 1;34(5):1435-9 - PubMed
  22. J Infect Dis. 1995 Aug;172(2):585-8 - PubMed
  23. J Lipid Res. 1995 Jun;36(6):1254-63 - PubMed
  24. Eur Heart J. 1999 Jan;20(2):121-7 - PubMed
  25. Infect Immun. 1996 Nov;64(11):4872-5 - PubMed
  26. Antimicrob Agents Chemother. 1999 Jun;43(6):1491-3 - PubMed
  27. Clin Sci (Lond). 2008 Apr;114(8):509-31 - PubMed
  28. Free Radic Res. 1996 Aug;25(2):181-92 - PubMed
  29. Circulation. 1999 Sep 28;100(13):1369-73 - PubMed
  30. Glycobiology. 1996 Apr;6(3):303-11 - PubMed
  31. J Infect Dis. 1998 Mar;177(3):725-9 - PubMed
  32. Curr Opin Infect Dis. 2000 Dec;13(6):583-591 - PubMed
  33. Arterioscler Thromb. 1992 Jul;12(7):789-99 - PubMed
  34. Curr Cardiol Rev. 2009 May;5(2):87-104 - PubMed
  35. Circ Res. 1994 Dec;75(6):1078-85 - PubMed
  36. JAMA. 1999 Feb 24;281(8):727-35 - PubMed
  37. Am Heart J. 1998 Aug;136(2):357-61 - PubMed
  38. Lancet. 1997 Aug 9;350(9075):404-7 - PubMed
  39. Ann Intern Med. 1996 Dec 15;125(12):979-82 - PubMed
  40. Circulation. 1998 Jul 28;98(4):300-7 - PubMed
  41. J Infect Dis. 2002 Nov 15;186(10):1469-73 - PubMed
  42. Lancet. 1993 Jan 30;341(8840):255-9 - PubMed
  43. J Biol Chem. 1989 Jun 15;264(17):10264-70 - PubMed
  44. CMAJ. 2000 Jul 11;163(1):49-56 - PubMed
  45. Arterioscler Thromb Vasc Biol. 2001 Jan;21(1):E1-8 - PubMed
  46. Infect Immun. 1998 Apr;66(4):1370-6 - PubMed
  47. Epidemiol Infect. 1998 Feb;120(1):93-9 - PubMed
  48. Circulation. 2001 Jan 23;103(3):351-6 - PubMed
  49. Clin Infect Dis. 2001 Aug 15;33(4):492-503 - PubMed
  50. J Lipid Res. 1995 Jul;36(7):1474-82 - PubMed
  51. Antimicrob Agents Chemother. 1999 Sep;43(9):2268-72 - PubMed
  52. APMIS. 1995 Nov;103(11):769-96 - PubMed
  53. Infect Immun. 1997 Feb;65(2):699-707 - PubMed
  54. Cytokine. 1994 Jan;6(1):87-91 - PubMed
  55. Scand J Infect Dis Suppl. 1997;104:30-3 - PubMed
  56. Ann N Y Acad Sci. 1982;401:102-16 - PubMed
  57. J Immunol. 2008 Apr 15;180(8):5490-8 - PubMed
  58. J Clin Invest. 1987 Jul;80(1):184-90 - PubMed
  59. J Biol Chem. 1997 Aug 22;272(34):20963-6 - PubMed
  60. Circ Res. 2008 Apr 25;102(8):888-95 - PubMed
  61. Stroke. 1998 Feb;29(2):404-10 - PubMed
  62. Lancet. 1997 Aug 9;350(9075):430-6 - PubMed
  63. J Clin Invest. 1999 Feb;103(4):571-7 - PubMed
  64. J Infect Dis. 1988 Aug;158(2):457-60 - PubMed
  65. J Infect. 1997 Sep;35(2):171-6 - PubMed
  66. Int J Immunopathol Pharmacol. 2009 Jan-Mar;22(1):9-14 - PubMed
  67. J Lipid Res. 1991 Jan;32(1):63-70 - PubMed
  68. Circulation. 1998 Feb 24;97(7):633-6 - PubMed
  69. Basic Res Cardiol. 1994;89 Suppl 1:41-6 - PubMed
  70. J Lab Clin Med. 2000 Sep;136(3):194-200 - PubMed
  71. Curr Opin Lipidol. 1997 Oct;8(5):268-74 - PubMed
  72. BMJ. 1997 May 17;314(7092):1456-7 - PubMed
  73. N Engl J Med. 1996 Jul 4;335(1):43-5 - PubMed
  74. Infect Immun. 1999 Nov;67(11):6048-55 - PubMed
  75. BMJ. 1999 Apr 17;318(7190):1035-9 - PubMed
  76. Atherosclerosis. 2008 Jul;199(1):154-61 - PubMed
  77. Cell. 1989 Oct 6;59(1):5-8 - PubMed
  78. Proc Natl Acad Sci U S A. 1990 Jul;87(13):5134-8 - PubMed
  79. Atherosclerosis. 2006 Jun;186(2):331-6 - PubMed
  80. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2910-3 - PubMed
  81. N Engl J Med. 1996 Jun 6;334(23):1526-9 - PubMed
  82. J Infect Dis. 1993 Apr;167(4):841-9 - PubMed
  83. Atherosclerosis. 1996 Oct 25;126(2):333-8 - PubMed
  84. Infect Immun. 2004 Apr;72(4):1843-55 - PubMed
  85. Metabolism. 1996 Sep;45(9):1069-79 - PubMed
  86. Curr Opin Lipidol. 1996 Oct;7(5):324-9 - PubMed
  87. Thromb Haemost. 2006 Jan;95(1):151-8 - PubMed
  88. J Infect Dis. 1998 Jul;178(1):274-7 - PubMed
  89. Eur Heart J. 1990 Aug;11 Suppl E:88-99 - PubMed
  90. Circulation. 1997 Feb 18;95(4):1062-71 - PubMed
  91. Clin Infect Dis. 1992 Nov;15(5):757-61 - PubMed
  92. Intern Med. 1998 Nov;37(11):913-6 - PubMed
  93. J Clin Invest. 1999 Mar;103(5):747-53 - PubMed
  94. Clin Diagn Lab Immunol. 1999 Nov;6(6):891-4 - PubMed
  95. Infect Immun. 1996 May;64(5):1614-20 - PubMed
  96. Annu Rev Biochem. 1983;52:223-61 - PubMed
  97. Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):130-1 - PubMed
  98. J Biol Chem. 1999 Feb 5;274(6):3764-71 - PubMed
  99. Free Radic Biol Med. 1996;20(5):707-27 - PubMed
  100. Microb Pathog. 1994 Apr;16(4):313-9 - PubMed
  101. Eur Heart J. 1993 Dec;14 Suppl K:62-5 - PubMed
  102. Microb Pathog. 1996 Nov;21(5):407-11 - PubMed
  103. Ann N Y Acad Sci. 1994 Jun 17;723:258-70 - PubMed
  104. J Clin Microbiol. 1995 Sep;33(9):2411-4 - PubMed
  105. Circulation. 2003 Jul 22;108(3):261-5 - PubMed
  106. Circulation. 2002 Sep 24;106(13):1659-63 - PubMed
  107. Nature. 1993 Apr 29;362(6423):801-9 - PubMed
  108. Arteriosclerosis. 1983 May-Jun;3(3):215-22 - PubMed

Publication Types